VEGFA and hereditary clear cell renal cell carcinoma: More recently, corroborative data from over 700 patients with renal cell carcinoma in a phase III placebo-controlled randomized trial of sorafenib confirmed that sorafenib therapy increased VEGF and decreased sVEGRF-2 levels [34].